- Stifel has reiterated a Buy rating and $85 price target on ChemoCentryx Inc (NASDAQ:CCXI) following the Q4 results.
- Analyst Dae Gon Ha says he is "perplexed" by the pronounced weakness on what he views as a positive-launch quarter.
- Ha tells investors in a research note that 127 patient start forms and 71% conversion rate strike is positive. In contrast, management's January 2022 commentary was perceived as cautious/negative by some $1 million in Q4 product sales beat consensus estimates.
- The analyst is more optimistic today on Tavneos' outlook, he adds.
- ChemoCentryx reported a Q4 EPS loss of $(0.58) which missed the analyst consensus estimate of $(0.50).
- The Company reported quarterly sales of $2.31 million, below the consensus estimate of $11.62 million, down 47% Y/Y.
- The Company held cash, cash equivalents of approximately $362.3 million. ChemoCentryx reported Tavneos US sales of $1.0 million.
- Price Action: CCXI shares are down 21.20% at $23.22 during the market session on the last check Wednesday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
See Why Is Stifel Analyst 'Perplexed' After ChemoCentryx Q4 Earnings
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks